| Features: |
| Psoralidin is a prenylated coumestan isolated primarily from Psoralea corylifolia (Babchi). It is not a classical anticancer drug. Psoralidin generally acts to suppress oncogenic signaling and survival pathways while promoting apoptosis in tumor cells. Reported effects (context-dependent, preclinical): -DOWNREGULATES pro-survival pathways (e.g., NF-κB, STAT3) -UPREGULATES apoptotic signaling (caspase activation) -MODULATES androgen receptor signaling in prostate cancer models -SENSITIZES tumor cells to chemo- and radio-induced stress This positions psoralidin as a biologic modulator, not a driver. Across cancer cell and animal models, psoralidin has been associated with: -Apoptosis induction -Caspase activation -Mitochondrial depolarization -Inflammatory pathway suppression -NF-κB inhibition -STAT3 attenuation -Hormone signaling modulation -Androgen receptor suppression (prostate cancer context) -Oxidative stress interaction -Redox imbalance tipping tumor cells toward death under stress Psoralidin is best described as chemopreventive or chemo-sensitizing, not chemoprotective |
| Source: HalifaxProj(promote) |
| Type: |
| Natural Killer (NK) cells are a type of lymphocyte in the immune system that play a crucial role in the body's defense against tumors and virally infected cells. NK cells can directly kill cancer cells through the release of cytotoxic granules containing perforin and granzymes. Perforin forms pores in the target cell membrane, allowing granzymes to enter and induce apoptosis (programmed cell death). NK cells produce various cytokines, such as interferon-gamma (IFN-γ), which can enhance the immune response and promote the activation of other immune cells, including macrophages and T cells. -Monoclonal Antibodies: Using antibodies that engage NK cells to target and kill cancer cells. -Cytokine Therapy: Administering cytokines like IL-2 or IL-15 to boost NK cell activity. |
| 4966- | PSO, | Psoralidin induces pyroptosis in both tumor cells and macrophages as well as enhances nature killer cell cytotoxicity to suppress hepatocellular carcinoma |
| - | vitro+vivo, | HCC, | HepG2 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:389 Target#:219 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid